Adaptimmune appoints two to board
This article was originally published in Scrip
Adaptimmune, a T-cell therapy company developing treatments for cancer and infectious diseases, has appointed Dr Jonathan Knowles to its board as a non-executive director, and Dr Helen Tayton-Martin joins the board as an executive director. Dr Knowles was formerly president of group research and a member of the executive committee at Roche, a post he held for 12 years. Dr Tayton-Martin has been COO of Adaptimmune since the company's foundation in 2008, having joined from Adaptimmune's predecessor companies, MediGene and Avidex.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.